Brief: Orchard Therapeutics Announces FDA Clearance Of IND Application For OTL-200 For Metachromatic Leukodystrophy
19/11/2020 12:30
Nov 19 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND
APPLICATION
FOR OTL-200 FOR METACHROMATIC LEUKODYSTROPHY (MLD)
* ORCHARD THERAPEUTICS PLC - CO HAS APPLIED FOR RMAT
DESIGNATION
FOR OTL-200 TO HELP FACILITATE ADDITIONAL DIALOGUE WITH FDA
Source text for Eikon: ID:nGNX76VYzG
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln